check_circleStudy Completed

Advanced Cancer

Phase 1 Dose-escalation PK/PD Trial in Advanced Cancer Patients

Trial purpose

Primary Objective: To evaluate the safety of escalating oral doses of RDEA119, a MEK inhibitor, in advanced cancer patients.
Secondary Objectives:
• To describe the initial PK of different doses of RDEA119 when given once orally on Day 1 of the study
• To describe the PK of different doses of RDEA119 when given orally as continuous dosing.
• To examine the inhibition of MEK products (p-ERK), cytokine products, and other protein biomarkers
• To expand the MTD dose cohort to evaluate the safety, tolerability and PK/PD of the recommended Phase 2 dose
• To explore the presence of genotype, PD markers, cell growth and a marker of apoptosis, in paired tumor biopsy samples of patients' tumors pre-dose and during dosing in a minimum of 10 patients in the expanded cohort

Key Participants Requirements

Sex

Both

Age

18 Years

Trial summary

Enrollment Goal
69
Trial Dates
November 2007 - August 2012
Phase
Phase 1
Could I Receive a placebo
No
Products
Refametinib (BAY86-9766)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
TGen Clinical Research Services at Scottsdale HealthcareScottsdale, 85258, United States
Completed
UCHSCAurora, 80045, United States
Completed
Roswell Park CancerBuffalo, 14263, United States

Primary Outcome

  • Safety will be assessed as adverse and drug related events, clinical laboratory test results (hematology, chemistry, coagulation, and urinalysis), vital signs, 12-lead electrocardiograms (ECGs), and physical examination
    date_rangeTime Frame:
    35 Days
    enhanced_encryption
    Safety Issue:
    Yes

Secondary Outcome

  • Pharmacokinetics and Pharmacodynamics
    date_rangeTime Frame:
    35 Days
    enhanced_encryption
    Safety Issue:
    No

Trial design

A Multi-Center Phase 1, Dose-Escalation Trial to Determine the Safety and Pharmacokinetics/Pharmacodynamics of RDEA119, A MEK Inhibitor, in Advanced Cancer Patients
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
N/A
Blinding
Open Label
Assignment
Single Group Assignment
Trial Arms
1